Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gilbert

Showing results (801-810 of 869) with videos related to

Pageof 87
Sort By:
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
The Journal of Infectious Diseases|January 12, 2018
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 TrialYouyi Fong, Xiaoying Shen, Vicki C Ashley, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Annals of the New York Academy of Sciences|January 14, 2022
Innovative vaccine approaches-a Keystone Symposia reportJennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
Pageof 87

Showing results (801-810 of 869) with videos related to

Sort By:
Pageof 87
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
The Journal of Infectious Diseases|January 12, 2018
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 TrialYouyi Fong, Xiaoying Shen, Vicki C Ashley, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Annals of the New York Academy of Sciences|January 14, 2022
Innovative vaccine approaches-a Keystone Symposia reportJennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
Pageof 87